TwinStrand Biosciences Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
113
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$50M
- Investors
-
11
TwinStrand Biosciences General Information
Description
Developer of a DNA sequencing therapy designed to identify ultra-low frequency genomic variants that are undetectable by conventional methods. The company's therapy offers highly sensitive and specific duplex sequencing technology offers data that can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, enabling researchers with clearer insights in applications ranging from residual cancer detection to genetic toxicology.
Contact Information
Website
www.twinstrandbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 3131 Elliott Avenue
- Suite 750
- Seattle, WA 98121
- United States
+1 (877) 000-0000
TwinStrand Biosciences Timeline
TwinStrand Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 30-Apr-2021 | $50M | 000.00 | 00000 | Completed | Generating Revenue |
| 7. Grant | 15-Jul-2019 | 00000 | 000.00 | Completed | Generating Revenue | |
| 6. Debt - PPP | 15-Apr-2020 | 00000 | 000.00 | Completed | Generating Revenue | |
| 5. Grant | 01-Jan-2020 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A2) | 30-Dec-2019 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. Grant | 01-Jan-2019 | 00.00 | 00.00 | Completed | Generating Revenue | |
| 2. Grant | 01-Jan-2018 | $2.3M | $6.1M | Completed | Generating Revenue | |
| 1. Seed Round | 13-Sep-2017 | $6.1M | $6.1M | Completed | Generating Revenue |
TwinStrand Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series A-1 | 1,665,992 | $0.000100 | 6% | $2.58 | $2.58 | 1x | $2.58 | 6.05% |
| Seed | 4,365,624 | $0.000100 | 6% | $1.52 | $1.52 | 1x | $1.52 | 15.85% |
TwinStrand Biosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a DNA sequencing therapy designed to identify ultra-low frequency genomic variants that are undetectable by
Biotechnology
Seattle, WA
113
As of 2022
000.00
0000
0000-00-00
00000000000
000.00
000000
d do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000000000000
Seattle, WA
00
As of 0000
000.00
0000
0000-00-00
000000&0
000.00
000000
lum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000000000000
Providence, RI
00
As of 0000
0000
00000000000
0000
Add Comparison
TwinStrand Biosciences Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Stratos Genomics | Formerly VC-backed | Seattle, WA | 00 | 000.00 | 000000&0 | 000.00 |
| 000000 | Venture Capital-Backed | Providence, RI | 00 | 0000 | 00000000000 | 0000 |
| 000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 00000000 | Accelerator/Incubator Backed | Ebersberg, Germany | 00 | 000000000000 |
TwinStrand Biosciences Patents
TwinStrand Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020321991-A1 | Methods and reagents for nucleic acid sequencing and associated applications | Pending | 01-Aug-2019 | 0000000000 | |
| US-20220220543-A1 | Methods and reagents for nucleic acid sequencing and associated applications | Pending | 01-Aug-2019 | 0000000000 | |
| CA-3146435-A1 | Methods and reagents for nucleic acid sequencing and associated applications | Pending | 01-Aug-2019 | 0000000000 | |
| EP-4007818-A1 | Methods and reagents for nucleic acid sequencing and associated applications | Pending | 01-Aug-2019 | 0000000000 | |
| US-20220119876-A1 | Methods and reagents for efficient genotyping of large numbers of samples via pooling | Pending | 16-Oct-2018 | C12Q1/6858 |
TwinStrand Biosciences Executive Team (8)
TwinStrand Biosciences Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chad Waite Jr. | The W Fund | Chairman | 000 0000 |
| Jesse Salk Ph.D | TwinStrand Biosciences | Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member | 000 0000 |
| Michael Pellini MD | Section 32 | Board Member | 000 0000 |
| Sivaramakichenane Somasegar | Madrona Venture Group | Board Member | 000 0000 |
| Stephen Dow | Self | Board Member | 000 0000 |
TwinStrand Biosciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
TwinStrand Biosciences Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Janus Henderson Investors | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Section 32 | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Soleus Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Madrona Venture Group | Venture Capital | Minority | 000 0000 | 000000 0 |